Amrein, Melissa http://orcid.org/0000-0003-4522-0894
Li, Xinmin S.
Walter, Joan
Wang, Zeneng
Zimmermann, Tobias
Strebel, Ivo
Honegger, Ursina
Leu, Kathrin
Schäfer, Ibrahim
Twerenbold, Raphael
Puelacher, Christian
Glarner, Noemi
Nestelberger, Thomas
Koechlin, Luca
Ceresa, Benjamin
Haaf, Philip
Bakula, Adam
Zellweger, Michael
Hazen, Stanley L.
Mueller, Christian
Clinical trials referenced in this document:
Documents that mention this clinical trial
Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD)
https://doi.org/10.1007/s00392-022-01992-6
Funding for this research was provided by:
Schweizerische Herzstiftung
Kommission für Technologie und Innovation
European Commission
Stiftung Kardiovaskuläre Forschung Basel
Universität Basel
Abbott Laboratories
Roche
Singulex
University of Basel
Article History
Received: 12 May 2021
Accepted: 10 February 2022
First Online: 26 February 2022
Declarations
:
: Dr. Walter reports a research grant from the Swiss Academy of Medical Sciences and the Bangerter Foundation (YTCR 23/17). Dr. Twerenbold reports receiving research support from the Swiss National Science Foundation (P300PB_167803), the Swiss Heart Foundation, the Swiss Society of Cardiology, the University Hospital of Basel, as well as speaker honoraria/consulting honoraria from Roche Diagnostics, Abbott Diagnostics, Siemens, Singulex and Brahms. Dr. Nestelberger received speaker honoraria from Beckman-Coulter. Dr. Koechlin has received a research grant from the University of Basel, the Swiss Academy of Medical Sciences and the Gottfried and Julia Bangerter-Rhyner Foundation, as well as the “Freiwillige Akademische Gesellschaft Basel”, outside the submitted work. Professor Mueller reports receiving research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the European Union, the Stiftung für kardiovaskuläre Forschung Basel, the University of Basel, the University Hospital Basel, Abbott, Beckman Coulter, Biomerieux, Brahms, Ortho Diagnostics, Roche, Siemens, Singulex, Sphingotec, as well as speaker honoraria/consulting honoraria from Abbott, Amgen, Astra Zeneca, Biomerieux, Boehringer Ingelheim, BMS, Brahms, Cardiorentis, Novartis, Roche, Sanofi, Siemens, and Singulex. Professor Hazen and Professor Wang were supported in part by grants from the National Institutes of Health and the Office of Dietary Supplements (P01HL147823, HL103866, HL126827, HL130819 and the Leducq Foundation). Mass spectrometry studies were performed on instruments housed in a facility supported in part by a Center of Excellence Award by Shimadzu Scientific Instruments. Professor Hazen and Professor Wang report being named as co-inventor on pending and issued patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics and being eligible to receive royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland HeartLab, Quest Diagnostics, and Procter & Gamble. SL Hazen also reports being a paid consultant for Procter & Gamble and having received research funds from Procter & Gamble and Roche Diagnostics.
: The Basel VIII study has been approved by the local ethics committee of Basel, Switzerland that is the Ethikkommission Nordwest- und Zentralschweiz (EKNZ) with the number (PB_2019-00001/EKBB 100/04).
: Each patient enrolled to the Basel VIII study has agreed to participate in the study via a written consent form.
: All authors agreed for publication of this manuscript.